Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36717819)

  • 1. Clinical and genomic features in patients with second primary glioblastoma following first primary renal cell carcinoma.
    Zhang GT; Liu Q; Zuo FX; Liu HJ; Wang SQ; Yuan Q; Liu AS; Hu K; Meng XL; Wang WJ; Qian HP; Wan JH; Cai HQ
    BMC Cancer; 2023 Jan; 23(1):104. PubMed ID: 36717819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of developing glioblastoma following non-CNS primary cancer: a SEER analysis between 2000 and 2018.
    Dadey DYA; Medress ZA; Sharma M; Ugiliweneza B; Wang D; Rodrigues A; Parker J; Burton E; Williams B; Han SS; Boakye M; Skirboll S
    J Neurooncol; 2023 Sep; 164(3):655-662. PubMed ID: 37792220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
    Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
    Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
    Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
    Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
    [No Abstract]   [Full Text] [Related]  

  • 6. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
    Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
    Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
    Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
    Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course.
    DiNatale RG; Gorelick AN; Makarov V; Blum KA; Silagy AW; Freeman B; Chowell D; Marcon J; Mano R; Sanchez A; Attalla K; Weng S; Voss M; Motzer RJ; Russo P; Coleman JA; Reuter VE; Chen YB; Chan TA; Reznik E; Tickoo SK; Hakimi AA
    Eur Urol Focus; 2021 Mar; 7(2):381-389. PubMed ID: 31813809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.
    Shu C; Wang Q; Yan X; Wang J
    Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathological features and prognosis of renal cell carcinoma with sarcomatoid differentiation].
    Jiang Y; Su G; Yu W; Li J; Lu Q; Li Y; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):823-6. PubMed ID: 26887511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating multi-platform genomic datasets for kidney renal clear cell carcinoma subtyping using stacked denoising autoencoders.
    Gu T; Zhao X
    Sci Rep; 2019 Nov; 9(1):16668. PubMed ID: 31723226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
    Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture.
    Michalova K; Tretiakova M; Pivovarcikova K; Alaghehbandan R; Perez Montiel D; Ulamec M; Osunkoya A; Trpkov K; Yuan G; Grossmann P; Sperga M; Ferak I; Rogala J; Mareckova J; Pitra T; Kolar J; Michal M; Hes O
    Ann Diagn Pathol; 2020 Feb; 44():151448. PubMed ID: 31918172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic Features and Prognosis of Sporadic Bilateral Renal Cell Carcinoma: A Series of 148 Cases.
    Qi N; Li T; Ning X; Peng X; Cai L; Gong K
    Clin Genitourin Cancer; 2017 Oct; 15(5):618-624. PubMed ID: 28648756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Renal cell carcinoma in patients with end-stage renal disease: a clinicopathological analysis].
    He B; Zhang W; Liu LN; Wang H; Zou YW; Jiang YX; Yu WJ; Shi HL; Liu Y; Li YJ
    Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):846-850. PubMed ID: 31775432
    [No Abstract]   [Full Text] [Related]  

  • 16. Analysis of clinicopathological and molecular features of ELOC(TCEB1)-mutant renal cell carcinoma.
    Wang Y; Zhao P; Wang L; Wang J; Ji X; Li Y; Shi H; Li Y; Zhang W; Jiang Y
    Pathol Res Pract; 2022 Jul; 235():153960. PubMed ID: 35653922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic Alterations of Renal Cell Carcinoma and Clinical Implications in the Chinese Population.
    Zhang S; Wang B; Zhang F; Ye J; Ge L; Ma L
    Med Sci Monit; 2019 Apr; 25():2959-2965. PubMed ID: 31007253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
    Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
    Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genomics of renal cell carcinoma and its role in renal mass biopsy.
    Salami SS; George AK; Udager AM
    Curr Opin Urol; 2018 Jul; 28(4):383-391. PubMed ID: 29708949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of extensive necrosis in renal cell carcinoma.
    Collins J; Epstein JI
    Hum Pathol; 2017 Aug; 66():108-114. PubMed ID: 28669641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.